Published in Blood on September 23, 2008
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol (2009) 0.89
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res (2012) 0.86
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant (2012) 0.83
Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol (2013) 0.82
Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clin Exp Immunol (2010) 0.80
Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant (2015) 0.75
Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation. Cancer Med (2013) 0.75
Active immunotherapy: current state of the art in vaccine approaches for NHL. Curr Oncol Rep (2012) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol (2004) 2.99
The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol (2006) 2.96
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood (2002) 2.79
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood (2007) 1.50
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol (2007) 1.48
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res (1996) 1.41
Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol (1993) 1.25
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood (2007) 1.18
Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood (1998) 1.15
Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant (2005) 1.08
The lymphopenic mouse in immunology: from patron to pariah. Immunity (2006) 1.00
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood (2007) 0.97
CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res (2003) 0.89
Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer (2004) 0.87
Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J Transl Med (2007) 0.83
Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.80
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell (2002) 3.21
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A (2009) 2.07
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood (2006) 1.94
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (2007) 1.88
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood (2003) 1.73
Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med (2006) 1.69
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma (2009) 1.68
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A (2003) 1.58
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A (2002) 1.49
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood (2003) 1.47
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev (2008) 1.22
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood (2013) 1.20
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer (2009) 1.19
Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma (2002) 1.18
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res (2002) 1.17
Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 1.12
What happened to the concept of the physician-scientist? Acad Med (2012) 1.11
Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood (2006) 1.11
BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol (2002) 1.09
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood (2002) 1.07
Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng (2005) 0.99
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn (2007) 0.96
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95
Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma (2009) 0.95
The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol (2009) 0.94
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol (2011) 0.93
Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol (2003) 0.92
A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A (2012) 0.91
Cancer vaccines: pessimism in check. Nat Med (2004) 0.91
Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol (2011) 0.90
Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochem Biophys Res Commun (2009) 0.90
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol (2012) 0.90
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res (2005) 0.90
Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol (2010) 0.90
In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res (2002) 0.89
Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system. Biotechnol Prog (2004) 0.88
Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med (2009) 0.88
Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev (2011) 0.88
Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood (2009) 0.88
Idiotype vaccination for lymphoma: moving towards optimisation. Leuk Lymphoma (2009) 0.87
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. Hematology Am Soc Hematol Educ Program (2000) 0.87
Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. Br J Haematol (2008) 0.87
Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods (2003) 0.87